临床 试验
- MYPHISMO: MYB and Tislelizumab Against Multiple Oncologies Trial (MYPHISMO)条件:分子:Tislelizumab
- Study of the Safety and Pharmacokinetics of Lifirafenib in Patients With Solid Tumors条件:晚期实体肿瘤分子:Lifirafenib
- BTK Inhibitor Zanubrutinib in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)条件:淋巴瘤分子:Zanubrutinib
- A Study Comparing Obinutuzumab and Zanubrutinib Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma条件:淋巴瘤分子:Zanubrutinib
- Zanubrutinib in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies条件:淋巴瘤, 白血病, 骨髓瘤分子:Zanubrutinib
- A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL条件:白血病, 淋巴瘤分子:Zanubrutinib
- A Study Comparing Zanubrutinib and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)条件:淋巴瘤分子:Zanubrutinib
- Study of BTK Inhibitor Zanubrutinib in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)条件:淋巴瘤分子:Zanubrutinib
- Study of BTK Inhibitor Zanubrutinib in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma条件:淋巴瘤分子:Zanubrutinib
- Study of Evaluate Efficacy and Safety of Zanubrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)条件:淋巴瘤分子:Zanubrutinib